00:19 , Mar 7, 2018 |  BC Extra  |  Company News

Management tracks: Alliance, Anika

Alliance Pharma plc (LSE:APH) said CEO John Dawson will step down, effective May 1. He will be succeeded by Deputy CEO Peter Butterfield. The company also said Chairman Andrew Smith has stepped down. Smith is...
07:00 , Sep 23, 2016 |  BC Extra  |  Clinical News

J&J six-week combo cures all HCV patients in Phase II cohort

All 20 patients receiving a six-week course of a triple-combination therapy from Johnson & Johnson (NYSE:JNJ) to treat HCV genotype 1 infection achieved an SVR12 in a Phase II study, according to J&J's partners Achillion...
07:00 , Aug 16, 2016 |  BC Extra  |  Top Story

Tioma raises $86M for anti-CD47 antibodies

Immuno-oncology play Tioma Therapeutics Inc. (Brisbane, Calif.) raised $86 million in a series A round co-led by RiverVest Venture Partners, Novo Ventures, Roche Venture Fund and SR One. Tioma also named John Donovan president and...
07:00 , Apr 11, 2016 |  BioCentury  |  Finance

Invest, not ingest

There are myriad reasons for pharma and big biotech to make investments in fledgling companies through corporate venture arms, but data suggest M&A is not one of them. The latest example is Nimbus Therapeutics LLC,...
07:00 , May 25, 2015 |  BioCentury  |  Strategy

You better you bet

Johnson & Johnson's deal with Achillion Pharmaceuticals Inc. ties up one of the last remaining and most advanced unpartnered HCV portfolios and gives the pharma what could be a best-in-class molecule to catch up in...
01:55 , May 20, 2015 |  BC Extra  |  Top Story

Achillion, Janssen partner to develop HCV combo

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) granted the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to develop and commercialize treatment regimens containing Achillion's HCV assets. Achillion's HCV pipeline includes ACH-3102, a pan-genotypic,...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Alios, J&J deal

Johnson & Johnson completed its acquisition of Alios for about $1.8 billion in cash (see BioCentury, Oct. 6). Alios BioPharma Inc., South San Francisco, Calif.   Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.   Business: Infectious   ...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Alios, J&J deal

Johnson & Johnson is acquiring Alios for about $1.8 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV) infection. In July, the oral nucleoside analog met...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

Winner takes Alios

Antiviral developer Alios BioPharma Inc. raised strategic investments from three pharmas, but they all lost out to Johnson & Johnson (NYSE:JNJ). With a $1.7 billion bid on Sept. 30, J&J netted a candidate in Phase...
03:26 , Oct 1, 2014 |  BC Extra  |  Top Story

J&J buying Alios for $1.75B

Johnson & Johnson (NYSE:JNJ) is acquiring Alios BioPharma Inc. (South San Francisco, Calif.) for $1.75 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV). In July, the...